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Abstract
An ongoing flood of comparative genomic data is identifying human lineage specific (HLS)
sequences of unknown function, and there is strong interest in investigating their functional
effects. Transgenic apes, our closest evolutionary relative, have the highest potential to express
HLS sequences as they are expressed in Homo sapiens and likewise experience harm from such
transgenic research. These harms render the conduct of this research ethically unacceptable in
apes, justifying regulatory barriers between these species and all other non-human primates for
transgenic research.
INTRODUCTION
The publication of the draft sequence of the common chimpanzee genome in September
2005 was heralded as an advance that confirmed what Darwin1 and Huxley2 posited more
than a century ago: humans share common ancestors with African great apes3,4. In addition
to highlighting vast homologies between human and chimpanzee DNA, primate comparative
genomics is also providing insights into the question of what makes members of Homo
sapiens different from their nearest evolutionary relatives.. There is great interest in
identifying the genetic factors that underlie the traits that are traditionally taken to be the
hallmarks of our species: higher cognition5, complex language and vocalizations systems6,
skin phenotypes7, immune and reproduction system function8,9, sensory perception10,11,
degree of self and social awareness12, and other idiosyncrasies of our physiology, anatomy
and behavior 13. While computational predictions of function can be made from large data-
sets, determining which sequences are functionally related to complex lineage-specific
phenotypes can likely be accomplished by experimental investigation.
One potentially appealing experimental strategy is to investigate functional effects of HLS
sequences in transgenic non-human primates (NHPs). Ideally, the species chosen for this
research should be those who share the greatest genetic similarity with Homo sapiens, to
increase the likelihood that they will express the HLS sequences in ways that give a clear
indication of their function in humans. While the long generation times of apes makes them
less than ideal for genetic studies, their highly similar genetic background with humans
makes them a particularly attractive host species for transgenic studies of the function of
HLS sequences. However, we argue that the scientific insights that can potentially be gained
by this approach are outweighed by ethical concerns regarding the generation of such
“humanized” apes. The same evolutionary proximity that makes this research strategy
attractive renders it ethically unacceptable in apes, including greater apes (chimpanzees,
orangutans, bonobos, gorillas) and lesser apes (gibbons), because apes have the greatest
potential to produce human-like phenotypes and, as such, carry a unique potential for harm.
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In addition to the human genome sequence14, we now have the complete draft genome
sequences of chimpanzee4 and rhesus macaque15. Draft assemblies are currently available
for the gorilla, orangutan, marmoset, and lemur (http://www.ensembl.org/index.html), and a
draft Neanderthal genome sequence has recently been published16. In addition, draft
sequences of bonobo and baboon are underway (http://www.genome.gov/10002154). These
data-sets are providing a rich and unprecedented resource for mining lineage-specific
genomic changes among humans and NHPs. Evolutionary genomics has already uncovered
a wide range of HLS sequences. Genes affected include those that show striking HLS
increases or decreases in copy number17,18,19, genes that have changed dramatically at the
sequence level specifically in humans20, and genes that show altered brain expression
between human and chimpanzee21,22.
These genes span a range of functional characteristics, from those with no known function to
those implicated in various anatomical and physiological processes5, including several
linked to higher cognitive functions20,22,23. We can expect that, as more and more primate
genomes are completed, the list of HLS genomic changes will significantly expand and
further stimulate interest in understanding the functional consequences of such changes.
This in turn can be expected to generate an increased interest in using transgenic animals as
a means of studying HLS gene function.
TRANSGENIC RESEARCH USING NHPs
For uniquely human sequences or genes, transgenic research using NHPs could likely be
accomplished with existing techniques, either through homologous exchange of HLS
sequence with homologous sequence of the transgenic host species or addition of HLS
sequences to the host genome24,25,26,27. However, new advances will be required to study
functional consequences of differences in expression, since precisely altering expression
levels in transgenic research by increasing copy number or modifying the regulatory region
of a gene remains technically challenging. Nevertheless, improving our abilities to control
the number and genomic location of copies of integrated transgenes and levels of temporal
and spatial expression is a high priority goal within human gene transfer research, due to the
critical implications for the safety and efficacy of human gene therapy and other treatments.
A common application of transgenic animal technology has been the generation of mouse
models to study a number of human disorders, including neurodegenerative disorders28,
autoimmune diseases29,30, and cancer31. Nevertheless, even though there are National
Institutes of Health-supported efforts aimed at “humanizing” mice by development of
transgenic strains that contain human-specific alleles (RFA-MH-08-050) and a recent study
has examined the function of human alleles of the FOXP2 gene in transgenic mice32, there
are limits to what scientists can learn about the function of human genetic sequences in mice
because of the significantly different genetic backgrounds of the two species. There are also
considerable anatomical and physiological differences between these species that may
interfere with such an approach. In particular, there are large differences in relative size and
composition between rodents and humans in areas of the brain associated with higher
cognition. Thus, the possibility of anything near human cognition resulting from HLS
sequences transferred to a mouse using conventional transgenic approaches is remote.
Recently there has been a shift towards using NHP models33. The creation of chimeras
through the interspecies transfer of stem cells is one means of exploring the function of the
HLS sequences. The ethical concerns raised by the interspecies transplantation of human
brain, retinal stem cells, and other cells to nonhuman embryos or fetuses are addressed in the
literature34,35,36,37. The production of chimeras entails the transfer of an entire genome to
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the host species, while the creation of transgenics, which is the focus of this article, indicates
the transfer a genomic sequences(s) to the host. The first transgenic NHP was produced in
2001, and in 2008 a rhesus macaque that expressed hallmark features of Huntington’s
Disease became the first transgenic monkey model of human disease, raising the hope of
ultimately developing new therapies38. Another experimental approach is the recently
reported generation of transgenic NHPs to study mitochondrial gene replacement in primate
offspring26. The goal of developing new therapeutic approaches using these methods is an
admirable one, yet it raises important ethical questions and points to the need to distinguish
between the use of apes and all other NHPs (“monkeys” hereafter).
The basic rationale for pursuing transgenic research on HLS sequences is that it could
provide important information regarding the basic scientific question of what makes
members of Homo sapiens different from their nearest evolutionary cousins. The research
continuum from bench to bedside suggests that results of transgenic research may also
produce clinical benefits, especially given that HLS gene variants have been found to be
disproportionately enriched in genomic locations implicated in human diseases19,21.
Another key factor is evidence that evolutionary mechanisms that have produced rapid
genomic changes in the human lineage often produce human disease as a byproduct25. It is
possible that HLS variants that affect human phenotype could provide important insights
into disorders and clinically relevant phenotypes that are difficult to study by other means,
including cognitive disease25, neurodegenerative disorders38, social behavior disorders such
as autism39, dementia40, speech articulation defects41,21, and gene delivery systems42 for
therapeutic use. Since this research is still in the early stages and the benefits still theoretical,
it is appropriate to examine proactively the ethical concerns related to NHP transgenic
research.
ANIMAL WELFARE REGULATIONS
The prospect of conducting transgenic NHP research differs according to country; no
international animal welfare regulations exist at present but the OIE World Assembly of
National Delegates adopted a 5th Strategic Plan for pursuing OIE global mission in animal
health and welfare in 2010 (http://www.oie.int/eng/session2010/press_p_releases.htm).
Currently, transgenic research involving all NHPs could be approved in countries, including
the United States and China, that have no specific bans43,44,45,46,47. The use of great apes
for most research is effectively banned in the United Kingdom, New Zealand, the
Netherlands, Austria, and Sweden48,49,50. The ban in Austria and Sweden also includes the
lesser apes51. And the European Union is now considering updates to their animal welfare
laws that would mirror requirements in the United Kingdom52,53. Although monkeys are
used for research in the United Kingdom, regulations require additional oversight, including
a special license for the individual researcher, project, and institution47,54.
Animal welfare regulations and guidelines vary around the world, but all share a
commitment to what is known as the Three Rs: replacement, reduction, and refinement. The
Three Rs state that animals should only be used if there is no alternative and, when animals
are necessary, only the most humane methods should be used on the smallest number of
animals required for scientific validity43,4549,55,56,57. However, the Three Rs are criticized
by some for not providing a way to give special consideration to certain species, such as
NHPs46.
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Predictive and Diagnostic Uncertainty in Transgenic NHP Research
The transfer of an HLS gene or genomic variant into an NHP could have a specific, discreet
effect that has a more or less dramatic impact on a phenotype of relevance to human
function. However, biomolecular systems are interdependent, and most genes appear to have
multiple functions that can be seemingly unrelated. So, such a transfer could just as easily
have a wide array of unexpected and/or deleterious effects. For example, even if gene
targeting could be carried out specifically, the plieotropic nature of most genes will often
make the phenotypic impact of a transgenic intervention extremely difficult to predict or
interpret and may not emerge immediate but only as offspring are produced, even if studied
first in other animals21,58. This uncertainty raises the risk of producing unanticipated harm
to transgenic NHPs. Moreover, if HLS gene transfer actually accomplishes its intended aim
and produces a measurable change in a “human-like” NHP phenotype, this would raise
another set of ethical concerns. Even if a transgenic NHP remotely displayed phenotypic
traits that made it only slightly more similar to a human…there would be further ethical
questions concerning the animal’s vulnerability to harm.
Ethical Obligations towards NHPs in Transgenic Research
The debate about animal welfare in general, and the use of primates in particular, is often
carried out in the literature in terms of “moral status”, a term meant to describe what entities
are owed in their own right rather than as instrumental value to others59,60. Moral status is
not an all or nothing assessment since ethically justified regulations allow research on
humans and prohibit capricious animal use. Additionally, consideration of our ethical
obligations to humans and animals is not dependent on inherent capacities alone, but also
includes relational elements. For example, this consideration is applied to humans who lack
many human capacities and to companion animals like cats, dogs, and horses that lack
higher order capacities. Merely labelling an entity as having or lacking moral status cannot
do the ethical work of sorting out our particular obligations. Rather, ethical obligations are
to be determined by carefully assessing the answers to at least five questions: What are the
goals of research? What is the probability of success? Which animals are to be used? What
effect will there be on the animals used? Are there any alternatives? These questions
represent a moderate approach to the ethics of animal research: they assume that some
animal research is warranted and can be ethically justified, but also recognize that not every
scientific finding automatically outweighs the interests and welfare of the animals that its
demonstration might require61.
There is a growing literature on ethical issues in the creation and research use of transgenic
and chimeric animals in general, and primates in particular. Some analysts try to articulate
the unique concerns in transgenic research in terms of the "unnaturalness" of "crossing
species boundaries," citing unspecified downstream evolutionary and ecological risks62,63.
Others turn to notions of "animal integrity" or "species-specific dignity" to try to focus their
critiques on the impact of transgenic manipulations on the animals themselves35,64,65,66.
This approach is headed in the right direction, but it usually remains at a relatively abstract
level that is hard to apply to the actual conduct of animal research. It can be both
strengthened and sharpened by considering the purely biological challenges that any
transgenic apes that actually express humanized phenotypes would face. At the far end of
the spectrum, of course, are cognitive changes that might give transgenic apes enough self-
awareness to appreciate the ways their lives are circumscribed and to suffer, albeit
immeasurably, in the full psychological sense of that term. But it is not necessary to go that
far. Imagine the life of the transgenic chimpanzee that, while no more self-aware than other
chimps, is hairless, walks erect, lacks long canine teeth, or vocalizes like a human. There
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may be no question of a "normal" primate life in the wild for this chimp: it is likely to be
condemned by its engineering to live in a human environment. Outside the laboratory, this
chimp could well be considered a grotesque curiosity and unusually susceptible to
exploitation and inappropriate treatment for commercial gain. Within the laboratory colony,
moreover, the transgenic chimp is unlikely to be able to be socially successful with its own
species either and potentially viewed as strange and an outcast by those without its
differences. Ill-suited for both worlds, the humanized chimp is likely to sustain more injuries
and encounter more privations than the unengineered inhabitants of either species.
Apes share many capacities with humans such as the capacity for attachment and empathy,
communication, internalization of social rules, giving, trading, revenge, social maintenance,
and attending to group boundaries. Such capacities could exacerbate the harms to these
animals. If "humanizing" expressions of HLS sequences only served to inhibit or destroy the
characteristics that these apes already share with us, we have harmed them, even from a
human "speciesist" point of view. Since it is hard to imagine a case of transgenic HLS
sequence research in apes in which these social harms and the physical welfare concerns
they generate would not arise, it is reasonable to conclude that this research will almost
never be ethically acceptable. For policy purposes, this conclusion supports higher
regulatory barriers, in terms of safeguards and review, against any transgenic HLS sequence
research with apes.
Of course, monkeys also display many of these same social and behavioral characteristics.
To that extent, should they enjoy the protections as apes when it comes to transgenic
research with HLS sequences? Clearly there is an evolutionary spectrum between the great
apes, monkeys, and lemurs, and any line-drawing that occurs across it will be to some extent
arbitrary. The evolutionary and genomic distance between monkeys and humans is great
enough to diminish the prospect that a simple HLS sequence insertion in a monkey genome
will produce human-like phenotypes, or that those phenotypes will be as socially
challenging for monkeys as they would be for apes. Because of the greater evolutionary
distance between humans and monkeys compared to humans and apes, more genetic
changes would be needed in monkeys to elicit a human-like phenotype than would be
needed if apes were used as the host species. Consequently, there is a greater chance that
using apes as HLS hosts would produce a transgenic with a human-like phenotype than if a
monkey were the host species. Accordingly, because apes would more easily be humanized,
and the traits would likely be more human-like than if a monkey host were the host species.
For this reason, such humanized apes would be at greater risk for exploitation. From the
ethical point of view, the more social and cognitive capacities primates possess, the
weightier our obligations to them become. However, if a line is needed for policy and
regulatory purposes, the line between the ape and monkeys is relatively clean. This reduced
risk of harm of a human-like phenotype, suggests that transgenic HLS sequence research
with monkeys may not always be ethically objectionable and could be regulated on a case-
by-case basis by institutional animal care and use committees, including public
representation in the form of a community member.
CONCLUSIONS
A few conclusions can be drawn from this discussion. First, because of the close
evolutionary genomic proximity, transgenic apes have the greatest potential to express HLS
sequences as they are expressed in Homo sapiens and consequently experience harm from
transgenic research. This is in part due to the fact that humanized transgenic apes would
likely exhibit traits that are the most human-like, putting them at greater risk of exploitation.
Second, the challenge of assessing our ethical obligations to “humanized” apes is profound.
The ethical concerns raised by the generation and use of apes as transgenic hosts to study
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HLS sequence function render this research ethically unacceptable, justifying regulatory
barriers between these species and monkeys. Concurrently, we recommend that the possible
use of monkeys in transgenic HLS research be examined on a case-by-case basis by animal
welfare review boards, with special attention paid to the unique issues in careful application
of the Three Rs in primate research. Some information regarding HLS gene function can be
potentially be obtained using HLS transgenic mice. Of course, another alternative would be
to use clues given to us by comparative identification of HLS sequences in further studies of
members of our own species. While the NHP genome is similar to ours, there are also
significant differences. Thus, there are limits to what we can learn about the function of HLS
variants until we study them in the human genome where they may exist as naturally-
occurring variations. By this more direct means we can potentially identify deficiencies or
mutations in HLS sequences, and phenotypes that seem to accompany these changes.
Human HLS research is also laden with serious ethical questions about what it might mean
for a human to lack the hallmarks of “humanness”, and how that research might be used and
potential harms and abuses avoided. Those ethical questions deserve their own further
analysis.
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